Summary from the Kidney Cancer Association's Inaugural Think Thank: Coalition for a Cure

Brian Rini, E. Jason Abel, Laurence Albiges, Axel Bex, James Brugarolas, Ronald M. Bukowski, Jonathan A. Coleman, Charles G. Drake, Robert A. Figlin, Andy Futreal, Hans Hammers, Thomas Powles, W. Kimryn Rathmell, Christopher J. Ricketts, Samra Turajlic, Christopher G. Wood, Bradley C. Leibovich

Research output: Contribution to journalComment/debatepeer-review

Abstract

Close to 74,000 cases of renal cell carcinoma (RCC) are diagnosed each year in the United States. The past 2 decades have shown great developments in surgical techniques, targeted therapy and immunotherapy agents, and longer complete response rates. However, without a global cure, there is still room for further advancement in improving patient care in this space. To address some of the gaps restricting this progress, the Kidney Cancer Association brought together a group of 27 specialists across the areas of clinical care, research, industry, and advocacy at the inaugural “Think Tank: Coalition for a Cure” session. Topics addressed included screening, imaging, rarer RCC subtypes, combination drug therapy options, and patient response. This commentary summarizes the discussion of these topics and their respective clinical challenges, along with a proposal of projects for collaboration in overcoming those needs and making a greater impact on care for patients with RCC moving forward.

Original languageEnglish (US)
Pages (from-to)167-175
Number of pages9
JournalClinical Genitourinary Cancer
Volume19
Issue number2
DOIs
StatePublished - Apr 2021

Keywords

  • Biomarkers
  • Clinical needs
  • Registry
  • Renal cancer
  • Renal cell carcinoma

ASJC Scopus subject areas

  • Oncology
  • Urology

Fingerprint

Dive into the research topics of 'Summary from the Kidney Cancer Association's Inaugural Think Thank: Coalition for a Cure'. Together they form a unique fingerprint.

Cite this